

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2185)**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR  
AND  
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board hereby announces that Mr. Jie YIN (陰杰) (“**Mr. Yin**”) has tendered his resignation as a non-executive Director with effect from the conclusion of the forthcoming AGM of the Company in order to devote more time to his other work commitments. Mr. Yin has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express their heartfelt gratitude to Mr. Yin for his valuable contributions to the Company during his tenure as a non-executive Director.

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

Following the resignation of Mr. Yin, the Board of Directors shall comprise 8 Directors. Therefore, the Board proposes to make amendments to the Articles of Association in order to reflect the changes in the number of Board members. Accordingly, it is intended that the following specific amendments should be made to the Articles of Association:

<b>Prior to the amendment</b>	<b>After the amendment</b>
<b>Chapter 10 Article 101</b>  The Company shall establish a Board of Directors, which shall comprise 9 directors. There shall be 2 executive directors, 4 non-executive directors, 3 independent non-executive directors who are not shareholders of the Company and do not hold any positions within the Company. There shall be one chairman of the Board of Directors.	<b>Chapter 10 Article 101</b>  The Company shall establish a Board of Directors, which shall comprise <u>8</u> 9 directors. There shall be 2 executive directors, <u>3</u> 4 non-executive directors, 3 independent non-executive directors who are not shareholders of the Company and do not hold any positions within the Company. There shall be one chairman of the Board of Directors.

Save for the aforesaid proposed amendments to the Articles of Association, the other provisions of the Articles of Association remain unchanged.

The proposed amendments to the Articles of Association are subject to the approval of the shareholders of the Company by way of a special resolution at the forthcoming AGM; and will come into effect after obtaining all necessary approvals, authorizations or registration (if applicable) from or filing with the relevant government or regulatory authorities. A circular of the Company containing, among other things, details in relation to the proposed amendments to the Articles of Association and a notice convening the AGM, will be despatched to the shareholders of the Company as soon as practicable.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

“AGM”	the forthcoming annual general meeting of the Company to be held on June 27, 2022
“Articles of Association”	the articles of association of the Company
“Board” or “Board of Directors”	the board of Directors of the Company
“Company”, “our Company”	Shanghai Bio-heart Biological Technology Co., Ltd. (上海百心安生物技術股份有限公司), a joint stock company incorporated in the PRC with limited liability on December 8, 2020, or, where the context requires (as the case may be), its predecessor with the same English name (上海百心安生物技術有限公司), a limited liability company established in the PRC on July 18, 2014
“Director(s)”	the director(s) of the Company or any one of them
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People’s Republic of China, May 12, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.*